[go: up one dir, main page]

UY29653A1 - Nuevos anticuerpos anti-madcam - Google Patents

Nuevos anticuerpos anti-madcam

Info

Publication number
UY29653A1
UY29653A1 UY29653A UY29653A UY29653A1 UY 29653 A1 UY29653 A1 UY 29653A1 UY 29653 A UY29653 A UY 29653A UY 29653 A UY29653 A UY 29653A UY 29653 A1 UY29653 A1 UY 29653A1
Authority
UY
Uruguay
Prior art keywords
new anti
madcam antibodies
antibodies
madcam
medicine
Prior art date
Application number
UY29653A
Other languages
English (en)
Inventor
Nicholas Pullen
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of UY29653A1 publication Critical patent/UY29653A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona nuevos anticuerpos anti-MAdCAM mejorados. También se incluyen usos de estos anticuerpos en medicina, en particular para el tratamiento de estados inflamatorios tales como enfermedad inflamatoria del intestino.
UY29653A 2005-07-08 2006-07-06 Nuevos anticuerpos anti-madcam UY29653A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69745305P 2005-07-08 2005-07-08

Publications (1)

Publication Number Publication Date
UY29653A1 true UY29653A1 (es) 2007-02-28

Family

ID=37637550

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29653A UY29653A1 (es) 2005-07-08 2006-07-06 Nuevos anticuerpos anti-madcam

Country Status (15)

Country Link
US (3) US20070009536A1 (es)
EP (1) EP1904531B1 (es)
JP (1) JP2009500390A (es)
AR (1) AR054539A1 (es)
AT (1) ATE483732T1 (es)
CA (1) CA2614314A1 (es)
DE (1) DE602006017373D1 (es)
DO (1) DOP2006000162A (es)
ES (1) ES2351057T3 (es)
GT (1) GT200600297A (es)
NL (1) NL1032132C2 (es)
PE (1) PE20070374A1 (es)
TW (1) TW200740844A (es)
UY (1) UY29653A1 (es)
WO (1) WO2007007173A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE602005026779D1 (de) * 2004-01-09 2011-04-21 Pfizer ANTIKÖRPER GEGEN MAdCAM
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR20080017094A (ko) * 2005-07-11 2008-02-25 화이자 리미티드 간 섬유증을 치료하기 위한 항-ＭＡｄＣＡＭ 항체 및항섬유성 캐스파아제 억제제의 신규한 조합물
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US20150010563A1 (en) * 2012-02-21 2015-01-08 Massachusetts Eye & Ear Infirmary Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9429577B2 (en) 2012-09-27 2016-08-30 Biocare Medical, Llc Anti-uroplakin II antibodies systems and methods
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
ES2720483T3 (es) 2013-02-28 2019-07-22 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti p40
EP3052522B1 (en) 2013-10-03 2019-12-11 Biocare Medical, LLC Anti-sox10 antibody systems and methods
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CA2916283C (en) 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
WO2017106326A1 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
EA202090286A1 (ru) 2017-07-14 2020-05-12 Пфайзер, Инк. АНТИТЕЛА К MAdCAM
CN114679909A (zh) * 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010810A1 (en) * 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1996024673A1 (en) * 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
ATE319745T1 (de) * 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU3986699A (en) * 1998-05-13 1999-11-29 Genentech Inc. Diagnosis and treatment of hepatic disorders
CA2342967A1 (en) * 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE602005026779D1 (de) * 2004-01-09 2011-04-21 Pfizer ANTIKÖRPER GEGEN MAdCAM

Also Published As

Publication number Publication date
US20070009536A1 (en) 2007-01-11
CA2614314A1 (en) 2007-01-18
DE602006017373D1 (de) 2010-11-18
US20090214558A1 (en) 2009-08-27
JP2009500390A (ja) 2009-01-08
EP1904531A2 (en) 2008-04-02
PE20070374A1 (es) 2007-05-12
TW200740844A (en) 2007-11-01
ATE483732T1 (de) 2010-10-15
US20110165167A1 (en) 2011-07-07
NL1032132C2 (nl) 2007-10-09
EP1904531B1 (en) 2010-10-06
AR054539A1 (es) 2007-06-27
US7935794B2 (en) 2011-05-03
NL1032132A1 (nl) 2007-01-09
WO2007007173A2 (en) 2007-01-18
WO2007007173A3 (en) 2007-05-10
ES2351057T3 (es) 2011-01-31
DOP2006000162A (es) 2007-01-31
GT200600297A (es) 2007-02-14

Similar Documents

Publication Publication Date Title
DOP2006000162A (es) Nuevos anticuerpos anti-madcan
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
EA201171367A1 (ru) Винилиндазолильные соединения
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EP4628094A3 (en) BAFF-R ANTIBODIES AND THEIR USES
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
ECSP099582A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
JO3346B1 (ar) مواد مضادة C5aR
CL2012000238A1 (es) Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
CL2008000875A1 (es) Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160912